Gregg C. Fonarow
Stanford University
Public scientific profile · Unclaimed
Built from public scholarly sources. Expertise is inferred by ScienceWe from publications and has not been confirmed by the scientist.
Top expertise
Heart Failure Treatment and Management
Strong evidence · 12 supporting papers · latest 2026
Hormonal Regulation and Hypertension
Strong evidence · 1 supporting paper · latest 2026
Diabetes Treatment and Management
Solid evidence · 4 supporting papers · latest 2026
Chronic Kidney Disease and Diabetes
Solid evidence · 1 supporting paper · latest 2026
Sepsis Diagnosis and Treatment
Solid evidence · 2 supporting papers · latest 2026
Atherosclerosis and Cardiovascular Diseases
Solid evidence · 1 supporting paper · latest 2026
Potassium and Related Disorders
Solid evidence · 2 supporting papers · latest 2026
Nutritional Studies and Diet
Solid evidence · 1 supporting paper · latest 2026
Publications (14)
Efficacy and Safety of Tirzepatide Versus Dulaglutide in Type 2 Diabetes With or Without Established Atherosclerotic Cardiovascular Disease: A Network Meta‐Analysis of Randomized Clinical Trials
2026DOIPMID 42706739
Practical Implementation of Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists in the Management of Heart Failure
2026DOIPMID 42790283
Target Versus Below-Target Dose ACE Inhibitors in U.S. Veterans with HFpEF: Differential Outcomes by CKD Status
2026DOIPMID 42530463
Inpatient Initiation of Target-Dose ACE Inhibitors and Lower Risk of Death or Kidney Failure in Veterans With HFrEF: Results From the National DCVA-HF Registry.
2026DOIPMID 42628680
Healthcare System Resilience and Adaptation: A 6-Year Analysis of Heart Failure Care in the Veterans Affairs System
2026DOIPMID 42670712
Initial Diuretic Strategy During Hospitalization for Heart Failure and Associated Outcomes: Insights From the TREAT-AHF Registry
2026DOIPMID 42575459
Dashboard-Directed Intervention to Improve Guideline-Directed Heart Failure Therapy for Veterans
2026DOIPMID 42462331
National Impact of Optimal Implementation of Guideline-Directed Medical Therapy in Heart Failure With Reduced Ejection Fraction
2026DOIPMID 42554537
Target-dose vs below-target-dose lisinopril and fosinopril in HFrEF with advanced CKD
2026DOIPMID 42713696
Racial and Ethnic Differences in Dietary Intake and Metabolic Profiles Among Adults with Heart Failure, Type 2 Diabetes, and Overweight or Obesity: A Secondary Analysis of the Pro-HEART Trial
2026DOIPMID 42654317
Get With The Guidelines–Heart Failure Hospital Participation and Its Association With Guideline-Directed Medical Therapy and Outcomes
2026DOIPMID 42683539
Forecasting Heart Failure Mortality in the United States Through 2050: A CDC WONDER Analysis
2026DOI
Cost-effectiveness of Evolocumab in Patients at High Cardiovascular Risk Without a Previous Myocardial Infarction or Stroke
2026DOI
Lost to Follow‐Up in Pragmatic Trials With Remote Follow‐Up: Insights From CONNECT‐HF and TRANSFORM‐HF
2026DOIPMID 42500873
Organizations in sourced records
Affiliation evidence only — not confirmed current employment.
- Stanford University
Source: OpenAlex · retrieved 2026-09-29
Source: ScienceWe Extractor · retrieved 2026-09-27